Scarica l'app Stockscreener
22.59
0.88%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IMVT Giù?
Forum
Previsione
Precedente Chiudi:
$22.79
Aprire:
$22.2
Volume 24 ore:
1.89M
Relative Volume:
1.08
Capitalizzazione di mercato:
$3.96B
Reddito:
-
Utile/perdita netta:
$-382.71M
Rapporto P/E:
-8.6221
EPS:
-2.62
Flusso di cassa netto:
$-325.64M
1 W Prestazione:
-4.84%
1M Prestazione:
+17.47%
6M Prestazione:
+56.77%
1 anno Prestazione:
-14.88%
Intervallo 1D:
$21.86
$22.85
Intervallo di 1 settimana:
$21.86
$24.73
Portata 52W:
$12.72
$29.49
Immunovant Inc Stock (IMVT) Company Profile
Nome
Immunovant Inc
Settore
Industria
Telefono
917-580-3099
Indirizzo
320 WEST 37TH STREET, NEW YORK, NY
Confronta IMVT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
22.59 | 3.99B | 0 | -382.71M | -325.64M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-14 | Iniziato | Truist | Hold |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-03-03 | Iniziato | Jefferies | Hold |
| 2025-01-03 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-10-09 | Reiterato | Oppenheimer | Outperform |
| 2024-03-28 | Iniziato | Oppenheimer | Outperform |
| 2024-03-13 | Iniziato | Goldman | Buy |
| 2024-02-20 | Iniziato | JP Morgan | Overweight |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-13 | Aggiornamento | UBS | Neutral → Buy |
| 2023-09-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | Iniziato | BofA Securities | Buy |
| 2023-04-25 | Iniziato | Citigroup | Buy |
| 2023-03-31 | Iniziato | Piper Sandler | Overweight |
| 2023-03-30 | Iniziato | Stifel | Buy |
| 2023-02-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-02-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-01-03 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | Downgrade | UBS | Buy → Neutral |
| 2021-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2021-08-03 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-01 | Downgrade | Stifel | Buy → Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-10-12 | Iniziato | Guggenheim | Buy |
| 2020-10-08 | Iniziato | Stifel | Buy |
| 2020-10-02 | Iniziato | Credit Suisse | Outperform |
| 2020-08-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Immunovant Inc Borsa (IMVT) Ultime notizie
Immunovant COO Gloria sells $298k in shares By Investing.com - Investing.com Nigeria
Immunovant COO Gloria sells $298k in shares - Investing.com
Immunovant Insider Sold Shares Worth $298,237, According to a Recent SEC Filing - MarketScreener
Immunovant Restructures R&D Leadership with CMO Departure - TipRanks
How analysts rate Immunovant Inc. stock todayInsider Selling & Technical Entry and Exit Tips - newser.com
Will Immunovant Inc. stock outperform value stocksTrade Exit Summary & Weekly Breakout Watchlists - newser.com
Is Immunovant Inc. stock affected by interest rate hikesJuly 2025 Gainers & Stepwise Trade Signal Implementation - newser.com
Can swing trading help recover from Immunovant Inc. losses2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
How Immunovant Inc. stock performs after earningsJuly 2025 Spike Watch & Community Consensus Trade Signals - newser.com
Responsive Playbooks and the IMVT Inflection - news.stocktradersdaily.com
Is Immunovant Inc. meeting your algorithmic filter criteriaPortfolio Value Summary & Safe Capital Growth Stock Tips - newser.com
Is Immunovant Inc. stock oversold or undervalued2025 Price Momentum & Weekly High Potential Alerts - newser.com
Key resistance and support levels for Immunovant Inc.Global Markets & Risk Adjusted Swing Trade Ideas - newser.com
Will Immunovant Inc. stock go up soonTrade Performance Summary & Free Low Drawdown Momentum Trade Ideas - newser.com
Sentiment analysis tools applied to Immunovant Inc.Weekly Stock Report & Low Risk High Win Rate Stock Picks - newser.com
Why Immunovant Inc. stock is popular among millennials2025 Technical Overview & Community Consensus Picks - newser.com
Why Immunovant Inc. stock is recommended by analystsWeekly Trade Analysis & Consistent Income Trade Ideas - newser.com
How institutional ownership impacts Immunovant Inc. stockMarket Activity Summary & Daily Profit Maximizing Trade Tips - newser.com
Immunovant, Inc. (NASDAQ:IMVT) Q2 2025 Earnings Call Transcript - Insider Monkey
Immunovant Inc Stock Analysis and ForecastStock Buyback Updates & Explosive Capital Growth Plans - earlytimes.in
Immunovant’s Earnings Call Highlights Clinical Success and Financial Strength - MSN
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus - MSN
Immunovant stock rating reiterated by Oppenheimer, cites progress in autoimmune portfolio - Investing.com South Africa
Immunovant, Inc. (NASDAQ:IMVT) Q2 2026 Earnings Call Transcript - Insider Monkey
Decoding Immunovant Inc (IMVT): A Strategic SWOT Insight - GuruFocus
Immunovant Reports Q2 2025 Financials and Clinical Progress - TipRanks
Immunovant (IMVT) Receives a Buy from H.C. Wainwright - The Globe and Mail
Immunovant Bets Big On Autoimmune Drug Pipeline Progress - Finimize
Earnings call transcript: Immunovant Q2 2025 shows innovation amid losses By Investing.com - Investing.com Nigeria
Earnings call transcript: Immunovant Q2 2025 shows innovation amid losses - Investing.com India
[10-Q] Immunovant, Inc. Quarterly Earnings Report | IMVT SEC FilingForm 10-Q - Stock Titan
IMMUNOVANT Earnings Results: $IMVT Reports Quarterly Earnings - Quiver Quantitative
[8-K] Immunovant, Inc. Reports Material Event | IMVT SEC FilingForm 8-K - Stock Titan
Immunovant Inc Azioni (IMVT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):